Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups

PSOGI and BIG RENAPE working groups

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. Objective: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. Material and methods: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. Results: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3–26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively. Conclusion: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy.

Original languageEnglish
Pages (from-to)1378-1383
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Neoplasm Metastasis
Carcinoma
Drug Therapy
Survival
Gallbladder
Databases

Keywords

  • Gallbladder
  • Hilar cholangiocarcinoma
  • Intra-hepatic cholangiocarcinoma
  • Klatskin

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{a52655e579864cf69bf5ec2dcac62e72,
title = "Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups",
abstract = "Background: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. Objective: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. Material and methods: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. Results: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3–26), macroscopically complete resection was obtained for 25 patients (73{\%}). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35{\%} vs. 18{\%}, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30{\%} and 10{\%} for surgical and chemotherapy group, respectively. Conclusion: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy.",
keywords = "Gallbladder, Hilar cholangiocarcinoma, Intra-hepatic cholangiocarcinoma, Klatskin",
author = "{PSOGI and BIG RENAPE working groups} and I. Amblard and F. Mercier and Bartlett, {D. L.} and Ahrendt, {S. A.} and Lee, {K. W.} and Zeh, {H. J.} and Levine, {E. A.} and D. Baratti and M. Deraco and P. Piso and Morris, {D. L.} and B. Rau and Tentes, {A. A.K.} and Tuech, {J. J.} and F. Quenet and E. Akaishi and M. Pocard and Y. Yonemura and G. Lorimier and D. Delroeux and L. Villeneuve and O. Glehen and G. Passot and J. Abba and K. Abboud and M. Alyami and C. Arvieux and N. Bakrin and Bereder, {J. M.} and D. Bouzard and C. Brigand and S. Carr{\`e}re and D. Delroeux and F. Dumont and C. Eveno and O. Facy and F. Guyon and R. Kianmanesh and {Lo Dico}, R. and G. Lorimier and F. Marchal and P. Mariani and P. Meeus and S. Msika and P. Ortega-Deballon and B. Paquette and P. Peyrat and N. Pirro and M. Pocard and Mao-Chih Hsieh",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.ejso.2018.04.023",
language = "English",
volume = "44",
pages = "1378--1383",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis

T2 - A multi-institutional cohort from PSOGI and BIG RENAPE groups

AU - PSOGI and BIG RENAPE working groups

AU - Amblard, I.

AU - Mercier, F.

AU - Bartlett, D. L.

AU - Ahrendt, S. A.

AU - Lee, K. W.

AU - Zeh, H. J.

AU - Levine, E. A.

AU - Baratti, D.

AU - Deraco, M.

AU - Piso, P.

AU - Morris, D. L.

AU - Rau, B.

AU - Tentes, A. A.K.

AU - Tuech, J. J.

AU - Quenet, F.

AU - Akaishi, E.

AU - Pocard, M.

AU - Yonemura, Y.

AU - Lorimier, G.

AU - Delroeux, D.

AU - Villeneuve, L.

AU - Glehen, O.

AU - Passot, G.

AU - Abba, J.

AU - Abboud, K.

AU - Alyami, M.

AU - Arvieux, C.

AU - Bakrin, N.

AU - Bereder, J. M.

AU - Bouzard, D.

AU - Brigand, C.

AU - Carrère, S.

AU - Delroeux, D.

AU - Dumont, F.

AU - Eveno, C.

AU - Facy, O.

AU - Guyon, F.

AU - Kianmanesh, R.

AU - Lo Dico, R.

AU - Lorimier, G.

AU - Marchal, F.

AU - Mariani, P.

AU - Meeus, P.

AU - Msika, S.

AU - Ortega-Deballon, P.

AU - Paquette, B.

AU - Peyrat, P.

AU - Pirro, N.

AU - Pocard, M.

AU - Hsieh, Mao-Chih

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. Objective: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. Material and methods: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. Results: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3–26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively. Conclusion: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy.

AB - Background: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. Objective: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. Material and methods: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. Results: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3–26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively. Conclusion: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy.

KW - Gallbladder

KW - Hilar cholangiocarcinoma

KW - Intra-hepatic cholangiocarcinoma

KW - Klatskin

UR - http://www.scopus.com/inward/record.url?scp=85049302941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049302941&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.04.023

DO - 10.1016/j.ejso.2018.04.023

M3 - Article

C2 - 30131104

AN - SCOPUS:85049302941

VL - 44

SP - 1378

EP - 1383

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 9

ER -